| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $22.9M | — | +49.4% |
| SG&A Expense | $5.0M | — | +47.8% |
| Operating Income | -$27.9M | — | -49.1% |
| Income Tax | $0 | — | — |
| Net Income | -$26.9M | — | -53.5% |
| EPS (Basic) | -$21.83 | — | +65.5% |
| EPS (Diluted) | -$21.83 | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $92.3M | +76.5% | — |
| Short-term Investments | $30.8M | -64.2% | — |
| Current Assets | $130.0M | -9.5% | — |
| Total Assets | $135.7M | -8.9% | — |
| Current Liabilities | $11.8M | -16.4% | — |
| Long-term Debt | $14.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$29.9M | — | -55.1% |
| Capital Expenditures | $318K | — | +3875.0% |
| Investing Cash Flow | $55.0M | — | +128.1% |
| Financing Cash Flow | $14.9M | — | — |
| Free Cash Flow | -$30.2M | — | -56.7% |
| +65.5% |
| — |
| — |
| Total Liabilities | $27.7M | +80.8% | — |
| Stockholders' Equity | -$264.2M | -10.7% | -37.9% |